MORINDA COREIA HAS AN ANTI-HELICOBACTER PYLORI EFFECT AGAINST THE MULTIDRUG-RESISTANT CLINICAL ISOLATE OF NORTH-EAST INDIA

Abstract

Objective: Antimicrobial resistance is a growing problem in Helicobacter pylori eradication which is a microaerophilic bacterium causing various gastroduodenal diseases. The present study has been designed to test the efficacy of Morinda coreia against the metronidazole clarithromycin and levofloxacin-resistant H. pylori strains isolated from the biopsy taken from the patient suffering from gastric erosion in Guwahati, Assam.Method: The antimicrobial activity of n-hexane and chloroform extract of M. coreia was tested against multidrug-resistant H. pylori isolate of Guwahati, Assam, by agar well method and microdilution method.Result: In the present study, the H. pylori strain resistant for metronidazole (minimal inhibitory concentration [MIC] >64 μg/mL), clarithromycin at (MIC >0.5 μg/mL), and levofloxacin at (MIC >1 μg/mL) was tested against the n-hexane and chloroform extract of M. coreia. Both the extracts of M. coreia showed good efficacy against the multidrug-resistant strain of H. pylori shown inhibition at 1.2 μg/mL with n-hexane extract and 2 μg/mL with chloroform extract of M. coreia. Conclusion: The prevalence of metronidazole-resistant ranges between 50% and 90% in the developing countries, including India, clarithromycin ranges from 0% to 15% in India, and levofloxacin ranges between 50% and 70% in India, so there is a need of alternative therapy for the eradication of this bacterium from the stomach. Hence, this study suggests that M. coreia, which has been used traditionally as a folk medicine for the treatment of many gastric diseases, has also shown good efficacy against the multidrug-resistant H. pylori strain of North-east India.